New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
12:41 EDTACT, JNJ, TEVA, ENDPChicago files lawsuit against Actavis, Endo, Janssen, Teva, Chicago Tribune says
Chicago has filed a lawsuit against Actavis (ACT), Endo Health Solutions (ENDP), Teva's (TEVA) Cephalon, Johnson & Johnson's (JNJ) Janssen Pharmaceuticals and Purdue Pharma, accusing the companies of concealing the risks associated with certain painkillers, the Chicago Tribune reports. The suit alleges the companies used "deceptive marketing practices to encourage doctors to prescribe and patients" to purchase more of these painkillers, leading to a rise in the "misuse and abuse" in the drugs. Reference Link
News For ACT;JNJ;TEVA;ENDP From The Last 14 Days
Check below for free stories on ACT;JNJ;TEVA;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
10:02 EDTENDP, ACT, TEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTENDP, ACT, TEVADeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTENDPEndo initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
18:40 EDTJNJOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
17:03 EDTJNJJohnson & Johnson announces $5B share repurchase program
Johnson & Johnson announced that its board has approved the repurchase of up to $5B of the company's common stock. The company had approximately 2.82B shares of common stock outstanding as of June 29.
17:01 EDTJNJJohnson & Johnson announces $5B share repurchase program
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
14:54 EDTJNJJohnson & Johnson weakness creates buying opportunity, says Argus
Subscribe for More Information
10:56 EDTJNJJohnson & Johnson reports 18% passive stake in Minerva
Subscribe for More Information
July 16, 2014
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
08:55 EDTJNJJohnson & Johnson pullback a buying opportunity, says Leerink
Leerink views the post-earnings pullback in shares of Johnson & Johnson as a buying opportunity. The firm expects "several" more quarters of outperformance and raised its price target for the stock to $115 from $110. It keeps an Outperform rating on J&J.
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
07:25 EDTJNJJohnson & Johnson should be bought on pullbacks, says RBC Capital
RBC Capital believes that Johnson & Johnson reported strong Q2 results, and the company raised its estimates for the company. The firm continues to recommend buying the stock on pullbacks.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use